

## **Zydus receives final approval from the USFDA for Clobetasol Propionate Cream**

---

*Ahmedabad, 17 October, 2018*

Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Cream, (US RLD – Temovate<sup>®</sup> Cream), 0.05%. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Clobetasol Propionate is a topical (for the skin) steroid used to treat inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.

The group now has 222 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*